Technical Data
S9500-30
Synuclein, alpha
Description:
Synuclein-alpha is the major component of Lewy bodies and Lewy neuritis in sporadic PD. dementia with Lewy Bodies and Lewy Body variant of AD. Lewy bodies are composed of truncated and phosphorylated intermediate neurofilament proteins, alpha synuclein, ubiquitin and associated enzymes. The synuclein phosphoproteins (15-20kDa) are small highly conserved proteins in vertebrates. The synuclein family includes alpha and beta synucleins and loosely related gamma-synuclein and synoretin. The expression is abundant in neurons and typically localized at presynaptic terminals.

Source: Tissue culture supernatant

Applications: Suitable for use in Western/Dot Blot, ELISA, Immunohistochemistry (Frozen and formalin-fixed paraffin-embedded tissues. No formic acid, enzyme or HIER required).

Recommended Dilution: Optimal dilutions to be determined by the researcher.

Storage and Stability: May be stored at 4įC for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20įC. Aliquots are stable for at least 12 months at -20įC. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG12B84Highly Purified
SizeStorageShippingSourceHost
100ul-20įCBlue IceHumanMouse
Concentration:
Not determined
Immunogen:
Purified E. coli produced human alpha-synuclein
Purity:
Purified by ammonium sulfate precipitation.
Form
Supplied as a liquid in PBS, pH 7.2, 0.1% sodium azide.
Specificity:
Recognizes human alpha-synuclein.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lucking, C.B., et al., (2000), "Alpha-synuclein and Parkinsonís disease", Cell Mol. Life Sci., 57(13-14): 1894-1908.
2. Trojanowski, J.Q., et al., (2000), "Fatal attractions of proteins. A comprehensive hypothetical mechanism underlying Alzheimerís disease and other neurodegenerative disorders", Ann. N.Y. Acad. Sci., 924: 62-67.
3. Conway, K.A., et al., (2000), "Accelerated oligomerization by Parkinsonís disease linked alpha-synuclein mutants", Ann. N.Y. Acad. Sci., 920: 42-45.
4. Kahle, P.J., et al., (2000), "Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinsonís disease-associated protein", Ann N.Y. Acad. Sci., 920:33-41.
5. Polymeropoulos, M.H., (2000), "Genetics of Parkinsonís disease", Ann. N.Y. Acad. Sci., 920: 28-32.
6. Spillantini, M.G., et al., (2000), "The alpha-synucleinopathies: Parkinsonís disease, dementia with Lewy bodies and multiple system atrophy"", Ann. N.Y. Acad. Sci., 920: 16-27.
7. McKeith, I.G., et al., (2000), "Clinical Lewy body syndromes", Ann. N.Y. Academy Science, 920: 1-8.
8. Braak, H., et al., (2000), "Pathoanatomy of Parkinsonís disease", J. Neurology, 247 Suppl., 2: II3-10.
9. Duda, J.E., et al., (2000), "Neuropathology of synuclein aggregates", J. Neuroscience Res., 61(2): 121-127.
10. Munoz, D.G., (1999), "Stains for the differential diagnosis of degenerative dementias", Biotech. Histochem., 74(6): 311-320.
11. Schulz, J.B., et al., (1999), "Molecular pathogenesis of movement disorders: are protein aggregates a common link in neuronal degeneration?", Curr. Opin. Neurol., 12(4): 433-439.
12. Hashimoto, M., et al., (1999),"Alpha-synuclein in Lewy body disease and Alzheimerís disease", Brain Pathol., 9(4): 707-720.
13. Clayton, D.F., et al., (1999), "Synucleins in synaptic plasticity and neurodegenerative disorders", J. Neurosci. Res., 59(1): 120-129.